137863-20-8

• 常用中文名：缬沙坦苄酯
• 常用英文名：Valsartan benzyl ester
• CAS号：137863-20-8
• 分子式：C₃₁H₃₅N₅O₃
• 分子量：525.641
• 发布时间：2018-05-15 08:00:00
• 更新时间：2026-06-30 14:41:03
• Valsartan benzyl ester is a Valsartan intermediate.

名称

• 中文名: 缬沙坦苄酯
• 英文名: (S)-Benzyl 2-(N-((2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)pentanamido)-3-methylbutanoate
• 中文别名: N-戊酰基-N-[[2'-(1H-四唑-5-基)[1,1'-联苯]-4-基]甲基]-L-缬氨酸苄酯; 缬沙坦杂质B(缬沙坦相关化合物C); 苄基缬沙坦; 原研CGP; 缬沙坦杂质2 (缬沙坦相关化合物C); N-((2'-(1H-四唑-5-基)-[1,1'-联苯]-4-基)甲基)-N-戊酰基-l-缬氨酸苄酯; 缬沙坦杂质27; (S)-2-[N-[[2'-(5-四唑基)-4-联苯基]甲基]戊酰氨基]-3-甲基丁酸苄酯; 缬沙坦相关物质C; 缬沙坦相关物C; 缬沙坦杂质2(缬沙坦RC C); 缬沙坦相关化合物C; 缬沙坦杂质B; 缬沙坦相关物质C 标准品; 缬沙坦杂质Ⅰ; 缬沙坦杂质C；缬沙坦苄酯; 缬沙坦杂质C; 缬沙坦 CGP49841; 缬沙坦杂质CGP49841; 缬沙坦RC C; 缬沙坦杂质B(缬沙坦苄酯); (S)-2-(N-((2'-(1H-四唑-5-基)-[1,1'-联苯]-4-基)甲基)戊酰胺基)-3-甲基丁酸苄酯
• 英文别名: T5MNNNJ ER BR D1NV4&YVO1R&Y1&1 &&L or S Form; Benzyl 2(S)-(N-((2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)pentanamido)-3-methylbutanoate; Benzyl N-pentanoyl-N-{[2'-(2H-tetrazol-5-yl)-4-biphenylyl]methyl}-L-valinate; BenzylN-((2'-(2H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-N-pentanoyl-L-valinate; Valstan-1; (S)-Benzyl 2-(N-((2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)pentanamido)-3-methylbutan; L-Valine, N-(1-oxopentyl)-N-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-, phenylmethyl ester; Valstan Related Compound C (J0M318); (S)-N-(1-benzyloxycbonyl-2-methyl-prop-1-yl)-N-pentanoyl-N-[2'-(1H-tetrazol-5-yl)bi-phenyl-4-ylmethyl]-amine; Valstan Impurity 2（Valstan RC C）; (S)-benzyl 2-(N-((2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)pentanamido)-3-methylbutanoate; Valstan Impurity BQ: What is Valstan Impurity B Q: What is the CAS Number of Valstan Impurity B Q: What is the storage condition of Valstan Impurity B Q: What e the applications of Valstan Impurity B; L-Valine, N-(1-oxopentyl)-N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-, phenylmethyl ester (9CI); (S)-N-Valeryl-N-([2'-(1H-tetrazole-5-yl)biphen-4-yl]methyl)valine benzyl ester; (S)-N-Valeryl-N-([2'-(1-H-tetrazole-5-yl)biphenyl-4-yl]-Methyl)valine benzyl ester; benzyl N-((2'-(1H-tetrazol-5-yl)-[1,1'- biphenyl]-4-yl)methyl)-N-pentanoyl- L-valinate; Benzyl (S)-2-[N-[[2'-(5-Tetrazolyl)-4-biphenylyl]methyl]pentanamido]-3-methylbutanoate; Benzyl N-pentanoyl-N-{[2'-(2H-tetrazol-5-yl)biphenyl-4-yl]methyl}-L-valinate; Valstan Impurity 2 (Valstan Related Compound C); Valstan impurity 1/Valstan Impurity B/(S)-Benzyl 2-(N-((2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)pentanamido)-3-methylbutanoate; (S)-benzyl2-(N-((2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)pentanamido)-3-methylbutanoate; Benzyl N-Pentanoyl-N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-D-valine; Valstan RC C; benzyl (2S)-3-methyl-2-[pentanoyl-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]amino]butanoate; N-(1-Oxopentyl)-N-[[2′-(2H-tetrazol-5-yl)[1,1′-biphenyl]-4-yl]methyl]-L-valine phenylmethyl ester; Benzyl (2S)-3-Methyl-2-[pentanoyl[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]amino]butanoate; Valstan Related Compound C (10 mg) (N-valeryl-N-{[2'-(1H-tetrazole-5-yl)biphenyl-4-yl]methyl}-L-valine benzyl ester); N-[2’-(1H-tetrazol-5-yl)biphenyl-4-yl methyl]-N-Valeryl-(L)-Valine benzyl ester; Valstan Benzyl Ester： (S)-N-Valeryl-N-([2'-(1-H-tetrazole)-5-yl)-biphenyl-4-yl]-Methyl)-valine benzyl ester; Benzyl 2-(N-((2'-(1H-tetrazol-5-yl); (S)-Benzyl 2-(N-((2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)pentanamido)-3-methylbutanoat; Valstan impurities27; Valsartan Impurity 2; Valstan Imp. B : Benzyl (2S)-3-methyl-2-[pentanoyl[[2'-(1H-tetrazol-5-yl) biphenyl-4-yl]methyl]amino]butanoate; Benzyl N-pentanoyl-N-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-L-valinate; Valstan Related Compound C (10 mg) ((S)-N-Valeryl-N-([2'-(1-H-tetrazole-5-yl)biphenyl-4-yl]-methyl)valine benzyl ester); Valstan Related CoMpound C; 3-methylbutanoate; Valstan Benzyl Ester; Valstan Impurity B/ Valstan Related Compound C (Valstan Benzyl Ester); (S)-benzyl 2-(N-((2'-(1H-tetrazol-5-yl); L-Valine, N-(1-oxopentyl)-N-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]- 4-yl]methyl]-, phenylmethyl ester; Valstan Impurity 2（Valstan Related Compound C）; Valstan Impurity B (Valstan Related Compound C); Valstan Impurity C; Valstan Impurity B; Phenylmethyl N-(1-oxopentyl)-N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-L-valinate; Valstan Related Compound C (N-valeryl-N-{[2''-(1H-tetrazole-5-yl)biphenyl-4-yl]methyl}-L-valine be; Benzyl (S)-N-(1-oxopentyl)-N-((2'-(1H-tetrazole-5-yl)-1,1'-biphenyl-4-yl)methyl)-L-valinate

物化性质

• 密度: 1.2±0.1 g/cm3
• 沸点: 720.1±70.0 °C at 760 mmHg
• 熔点: >71° C(dec.)
• 分子式: C₃₁H₃₅N₅O₃
• 分子量: 525.641
• 闪点: 389.3±35.7 °C
• 精确质量: 525.273987
• PSA: 101.07000
• LogP: 7.16
• 蒸汽压: 0.0±2.3 mmHg at 25°C
• 折射率: 1.589
• 储存条件: 室温

安全

• 危害码 (欧洲): Xn

合成路线

137864-44-9 ~90% 137863-20-8

文献：ENANTIA, S. L. Patent: WO2006/67216 A2, 2006 ; Location in patent: Page/Page column 29 ; WO 2006/067216 A2

137864-22-3 ~% 137863-20-8

文献：WO2005/49588 A1, ; Page/Page column 6 ;

676129-93-4 638-29-9 ~% 137863-20-8

文献：WO2004/26847 A1, ; Page 26; 32-33 ; WO 2004/026847 A1

67-56-1 137864-44-9 ~0% 137863-20-8 596-31-6

文献：ZENTIVA, a.s. Patent: WO2005/21535 A2, 2005 ; Location in patent: Page/Page column 15 ;

1315376-91-0 ~% 137863-20-8

文献：Organic Process Research and Development, , vol. 15, # 5 p. 986 - 988

上下游产品

上游产品  5
137864-44-9 137864-22-3 676129-93-4 638-29-9
67-56-1
下游产品  1
137862-53-4